Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Cash from Operating Activities
Exelixis Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exelixis Inc
NASDAQ:EXEL
|
Cash from Operating Activities
$333.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Exelixis Inc's Cash from Operating Activities?
Cash from Operating Activities
333.3m
USD
Based on the financial report for Dec 29, 2023, Exelixis Inc's Cash from Operating Activities amounts to 333.3m USD.
What is Exelixis Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-4%
Over the last year, the Cash from Operating Activities growth was -8%. The average annual Cash from Operating Activities growth rates for Exelixis Inc have been 17% over the past three years , -4% over the past five years .